GlassScriptPhysician profile
Wei Ling Lau
NPI 1558572032
$3,764.87
in general payments reported to CMS, 2019-2025
14 companies · $25.55 in 2025
The $25.55 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2021: $65.58 · 2022: $3,072 · 2023: $227 · 2024: $214 · 2025: $25.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $440 · Education: $27.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $439.65 |
| Education | $27.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,887.50 | 2022 | |
| Baxter Healthcare | $234.49 | 2022-2024 | Renal - Acute |
| Fresenius USA Marketing, INC. | $138.79 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Travere Therapeutics, INC. | $108.21 | 2023 | |
| Amgen INC. | $91.43 | 2019 | |
| Viiv Healthcare Company | $66.99 | 2023 | Dovato |
| Aurinia Pharma U.S., INC. | $53.15 | 2022 | |
| Glaxosmithkline, LLC. | $38.93 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $29.29 | 2024 | Jynarque |
| Calliditas Therapeutics US INC. | $27.20 | 2023 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $25.00 | 2024 | |
| Akebia Therapeutics INC | $23.57 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.63 | 2021 | |
| Novo Nordisk INC | $17.69 | 2024 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Ling Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.